Gonorrhea Treatment: New Antibiotic Zoliflodacin Shows Promise Against Resistance

The landscape of gonorrhea treatment is shifting, with a new potential option on the horizon. Recent research highlights the effectiveness and safety of zoliflodacin, an antibiotic representing the first new oral therapy for gonorrhea in decades. This development arrives at a critical juncture, as Neisseria gonorrhoeae, the bacterium causing gonorrhea, demonstrates increasing resistance to existing treatments.

Gonorrhea is a significant global public health concern. The World Health Organization (WHO) estimates that in 2020, approximately 82.4 million new infections occurred worldwide among adults aged 15 to 49 years. Untreated gonorrhea can lead to serious complications, including pelvic inflammatory disease, infertility, and disseminated infections like septic arthritis. Infection with N. Gonorrhoeae increases the risk of acquiring or transmitting HIV.

The Challenge of Antimicrobial Resistance

A key challenge in managing gonorrhea is the bacterium’s remarkable ability to develop resistance to various antibiotic classes. Currently, extended-spectrum cephalosporins, specifically ceftriaxone, remain the primary empirical first-line treatment option. However, resistance rates to fluoroquinolones and azithromycin are rising globally, and established treatment regimens involving ceftriaxone are increasingly under pressure. Recent studies demonstrate a high susceptibility to zoliflodacin internationally, even among strains resistant to ceftriaxone and azithromycin.

Zoliflodacin is a novel spiropyrimidinetrione that showed non-inferiority to the recommended ceftriaxone plus azithromycin treatment in a recent phase III randomized controlled trial. Researchers evaluated the susceptibility of zoliflodacin against nearly 3,000 contemporary gonococcal isolates collected between 2021 and 2024 from eight countries participating in the WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP). These countries span the WHO Southeast Asian, Western Pacific, and African Regions.

Study Findings and Geographic Distribution

The study, published in IJID Regions, revealed high activity of zoliflodacin, with minimum inhibitory concentrations (MICs) ranging from 0.001 to 1 mg/l, and a typical MIC of 0.032 mg/l. The majority of isolates exhibited a wild-type profile, indicating good susceptibility. However, two isolates from Cambodia showed elevated MICs of 0.5 mg/l and 1 mg/l, and also carried a specific mutation (GyrB D429N) associated with increased zoliflodacin MICs. These findings underscore the importance of ongoing surveillance for emerging resistance.

The participating countries in the study included Indonesia, Thailand, Cambodia, the Philippines, Viet Nam, Malawi, South Africa, and Uganda. This broad geographic representation is crucial, as patterns of antimicrobial resistance can vary significantly between regions.

Understanding MICs and Mutations

Minimum inhibitory concentrations (MICs) are a standard measure of antibiotic susceptibility. They represent the lowest concentration of an antibiotic that inhibits the visible growth of a bacterium. Higher MICs generally indicate reduced susceptibility. The GyrB D429N mutation identified in the Cambodian isolates suggests a potential mechanism of resistance to zoliflodacin, highlighting the demand for continued monitoring of genetic changes in the bacterium.

Implications for Treatment Guidelines

The WHO recognizes N. Gonorrhoeae as a high-priority pathogen due to widespread antimicrobial resistance. The Global Sexually Transmitted Infections Programme at the WHO leads the development and implementation of strategies to eliminate sexually transmitted infections as public health threats. The emergence of zoliflodacin, alongside another promising therapy called gepotidacin, offers renewed hope in the fight against this increasingly resistant infection.

While the study results are encouraging, it’s important to note that zoliflodacin is not yet widely available. Further clinical development and regulatory approvals are necessary before it can become a standard treatment option. The researchers emphasize the need for cautious and monitored introduction of zoliflodacin, coupled with continuous international resistance surveillance.

What’s Next: Surveillance and Further Research

The ongoing surveillance efforts of the WHO EGASP are vital for tracking the emergence and spread of antimicrobial resistance in N. Gonorrhoeae. This surveillance data informs treatment guidelines and helps to identify areas where new interventions are most needed. Continued research is also essential to understand the mechanisms of resistance to zoliflodacin and to develop strategies to mitigate its spread.

The development of new diagnostic tools to guide treatment choices is also a priority. As multiple organizations work to develop new drugs, the WHO recommends the AWaRe approach (Access, Watch and Reserve) for antibiotic stewardship, aiming to ensure that antibiotics are used appropriately and that new drugs remain effective for as long as possible.

For individuals concerned about gonorrhea or other sexually transmitted infections, it is crucial to seek testing and treatment from a qualified healthcare provider. Public health resources, such as those provided by the WHO and national health agencies, offer valuable information and guidance.